dobutamine /kg/min

Phase 2Small molecule

IInstituto de Investigación Hospital Universitario La Paz

dobutamine /kg/min is one of 5 small molecule programs targeting Infants. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfantsRecruiting

InfantsPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Infants

#DrugCompanyPhaseTrials

Aranesp

Amgen

Phase 2

2 2

Dopram

HHikma Pharmaceuticals LLC

Phase 3

1 3

Cysteine Hydrochloride

Novartis

Phase 1

1 4

dobutamine /kg/min

IInstituto de Investigación Hospital Universitario La Paz

Phase 2

1 5

Ivig

Argenx

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1/2Recruiting

Infants

NCT06878742

Clinical

Trials by Indication[1]

Infants1 trial

Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants

Recruiting·IInstituto de Investigación Hospital Universitario La Paz·Phase 1/2·NCT06878742·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dobutamine /kg/min. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dobutamine /kg/min compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dobutamine /kg/min. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto de Investigación Hospital Universitario La Paz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstituto de Investigación Hospital Universitario La Paz

dobutamine /kg/min

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Infants1 trial

References

Drug Info

Quick Facts

Related News